目的 探討采用癲癇康膠囊聯(lián)合奧卡西平治療癲癇的臨床療效。方法 選取荊州市第一人民醫(yī)院2015年5月-2017年5月收治的癲癇患者163例，隨機(jī)分成對照組（81例）和治療組（82例）。對照組患者口服奧卡西平片，起始劑量150 mg/d，然后加量1次/2周，最大量600 mg/d維持治療，2次/d；治療組患者在對照組的基礎(chǔ)上口服癲癇康膠囊，3粒/次，3次/d。兩組患者均治療3個月。觀察兩組患者臨床療效，同時比較治療前后兩組患者同型半胱氨酸（Hcy）水平、平均癥狀控制時間和癲癇發(fā)作次數(shù)及精神狀態(tài)和日常生活能力評分。結(jié)果 治療后，對照組和治療組臨床有效率分別為83.95%和95.12%，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者Hcy水平較治療前顯著升高（P<0.05），兩組平均癥狀控制時間和癲癇發(fā)作次數(shù)顯著減少（P<0.05），且治療后治療組平均癥狀控制時間和癲癇發(fā)作次數(shù)明顯少于對照組（P<0.05）。治療后，兩組患者精神狀態(tài)評分顯著升高（P<0.05），日常生活能力評分顯著降低（P<0.05），且治療組患者兩項評分明顯優(yōu)于對照組（P<0.05）。結(jié)論 癲癇康膠囊聯(lián)合奧卡西平治療癲癇患者療效顯著，不良反應(yīng)發(fā)生率低，具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the clinical efficacy of Dianxiankang Capsules combined with oxcarbazepine in treatment of epilepsy. Methods Patients (163 cases) with epilepsy in Jingzhou First people's Hospital from May 2015 to May 2017 were randomly divided into control (81 cases) and treatment (82 cases) groups. Patients in the control group were po administered with Oxcarbazepine Tablets, the initial dosage was 150 mg/d, then increased once every 2 weeks, and the maximum dose was 600 mg/d for maintenance treatment, twice daily. Patients in the treatment group were po administered with Dianxiankang Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacy was evaluated, and the Hcy level, the average time of symptom control and seizure frequency, the mental state and activity of daily living in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 83.95% and 95.12% respectively, and there were differences between two groups (P<0.05). After treatment, the Hcy levels in two groups were significantly increased (P<0.05), the average time of symptom control and seizure frequency was significantly decreased (P<0.05), and the average time and frequency in the treatment group after treatment was significantly less than that in the control group (P<0.05). After treatment, the mental state scores in two groups were significantly increased (P<0.05), the activity of daily living scores were significantly decreased (P<0.05), and the two scores in the treatment group after treatment were significantly better than those in the control group (P<0.05). Conclusion Dianxiankang Capsules combined with oxcarbazepine in treatment of epilepsy has significant clinical effect with low adverse reactions incidence, which has a certain clinical application value.